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Static magnetic field (SMF) therapy, applied via a permanent magnet attached to the skin,
is used by people worldwide for self-care. Despite a lack of established SMF dosage and
treatment regimens, multiple studies are conducted to evaluate SMF therapy effectiveness. Our
objectives in conducting this review are to:(i) summarize SMF research conducted in humans;
(ii) critically evaluate reporting quality of SMF dosages and treatment parameters and
(iii) propose a set of criteria for reporting SMF treatment parameters in future clinical trials.
We searched 27 electronic databases and reference lists. Only English language human studies
were included. Excluded were studies of electromagnetic fields, transcranial magnetic stimula-
tion, magnets placed on acupuncture points, animal studies, abstracts, posters and editorials.
Data were extracted on clinical indication, study design and 10 essential SMF parameters.
Three reviewers assessed quality of reporting and calculated a quality assessment score for each
of the 10 treatment parameters. Fifty-six studies were reviewed, 42 conducted in patient
populations and 14 in healthy volunteers. The SMF treatment parameters most often and most
completely described were site of application, magnet support device and frequency and
duration of application. Least often and least completely described were characteristics of the
SMF: magnet dimensions, measured field strength and estimated distance of the magnet from
the target tissue. Thirty-four (61%) of studies failed to provide enough detail about SMF
dosage to permit protocol replication by other investigators. Our findings highlight the need
to optimize SMF dosing parameters for individual clinical conditions before proceeding to
a full-scale clinical trial.
Introduction
The application of permanent magnets for treating
specific medical problems such as arthritis, chronic pain
syndromes, wound healing, insomnia, headache and
others has steadily increased during the last decade.
Data Research-2000 reported $350 million in sales of
therapeutic magnets in the USA and $4 billion
worldwide in 1999. Magnets marketed directly to con-
sumers are considered safe by the National Center of
Complementary and Alternative Medicine (NCCAM)
http://nccam.nih.gov/health/magnet/magnet.htm.
Results from basic science research demonstrating
certain biological effects of static magnetic field (SMF)
therapy provide a rationale for investigating potential
clinical benefits of SMFs (1–5). In addition, NCCAM
has funded human studies to evaluate the effectiveness
of SMFs for patients with fibromyalgia (6) and carpal
tunnel syndrome (7). Despite the lack of scientific
recommendations for SMF dosage and treatment
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properly cited.regimens, multiple clinical trials have been conducted to
evaluate SMF efficacy. Dosing parameters such as the
optimal SMF strength, frequency and duration of magnet
application and at what time point during the course of
an illness or injury the SMF should be applied, are not
established for any specific clinical indication.
As we begin to evaluate whether SMF therapy is
efficacious in humans, a critical need exists for
understanding and precisely defining SMF dosages and
treatment regimens. Our objectives for this critical review
are to: (i) summarize SMF studies involving the applica-
tion of permanent magnets in humans; (ii) critically
evaluate the reporting quality of 10 essential SMF dosing
and treatment parameters and (iii) propose a set of
criteria for reporting SMF treatment parameters in future
clinical trials.
This review does not report clinical outcomes because,
during a preliminary evaluation of the identified studies,
it was apparent that many lacked a sufficiently detailed
description of SMF dosage and treatment parameters to
characterize the SMF dose delivered to the target tissue.
We reasoned that if the SMF dose were inadequate or
inappropriate for the clinical indication, inferences drawn
from the reported results might be misleading.
Methods
Data Sources and Search Strategy
A professional librarian (NH) searched 27 electronic
databases from the time each database was developed
through September 30, 2006, to identify clinical studies
involving the use of SMF in humans (Table 1). Various
search strategies were employed depending on the size
and scope of the database. In some cases, a simple
keyword search using the term ‘magnet’ was sufficient to
retrieve relevant articles with reasonable precision and
recall. In other cases, a more sophisticated strategy
involving multiple synonyms for SMF therapy, subject
headings, truncation and excluded terms was required.
The primary author examined the results of the searches
to identify articles for analysis, screening by title, abstract
when it was available and full text where necessary.
The bibliographies from relevant original research,
reviews (8–10), and a key textbook in the SMF field
(11) were searched to identify additional references.
Inclusion and Exclusion Criteria
Studies were selected for inclusion using the following
criteria.
Publication type
Only English language articles were identified due to
limited funding for accurate translation. Abstracts,
posters and editorials were excluded because they were
unlikely to provide sufficient information with which to
evaluate the SMF treatment parameters.
Study design
Clinical trials, case series, case reports and observational
studies were included because our goal was to summarize
and evaluate all SMF treatment parameters that have
been described.
Clinical indication
We included studies involving any clinical diagnosis
or medical condition in humans. Studies evaluating
Table 1. Databases searched
Database Coverage dates
Acubriefs.com 1999 till present
Agency for Healthcare Research
and Quality (AHRQ) website
Website: no coverage dates given
Alt HealthWatch 1984 to September 2006
AMED ca. 1980 till present
Annual Reviews Online 1932–1999
Applied Science and Technology
Index
1983 till present
ArticleFirst 1990 till present
BIOSIS Previews 1990 till present
China Academic Journals (CAJ) 1994 till present
CINALH 1982 till present
Datadiwan Unable to determine; no response
from database producer
DIMDI (German Institute of
Medical Documentation and
Information)
Federated search of multiple
databases – various coverage
dates
Dissertation Abstracts
International
1861 till present
EMBASE.com 1974 till present+MEDLINE
ExtraMED 1992–2000
Global Health 1973 till present
HOM-INFORM (British
Homeopathic Library)
Unable to determine; no response
from database producer
Index to Chiropractic Literature 1985 till present
JICST–Eplus—Japanese Science &
Technology
1985 till present
MANTIS 1900 till present
MedicLatina 1998 till present
Natural Standard N/A (Periodically updated-
monograph)
NHS Centre for Reviews and
Dissemination
1994 till present
PASCAL 1973 till present
PubMed 1950 till present
ScienceDirect Health & Life
Sciences
1996 till present
SPORTDiscus 1830 till present
134 Static magnetic field therapyphysiological change as a result of magnet application in
healthy volunteers were also included.
Type of magnetic field therapy
Only studies involving the application of SMFs via
a permanent magnet were included. Excluded were
studies reporting on electromagnetic field therapy,
magnetic fields generated by applying DC to a coil,
transcranial magnetic stimulation. Also excluded were
studies reporting on the use of magnets on acupuncture
points. We believe the stimulation of acupuncture points
by means of a magnetic field may work via a systemic
mechanism (12) different from that occurring as a result
of a magnetic field applied directly to an anatomical/
pathological target tissue.
Data Extraction
Data were extracted from each article on clinical
indication, study design and 10 essential SMF treat-
ment parameters. An ‘essential treatment parameter’
was defined as a key component of the SMF dosage or
treatment regimen that needed to be clearly described
to characterize the magnetic field dose that was delivered
to the target tissue. The 56 articles (6, 13–67) that met
our inclusion/exclusion criteria were randomly distributed
to five data extractors.
Quality Assessment (QA) for Reporting SMF
Treatment Parameters
A QA score was developed to quantify how completely
each of 10 dosing parameters: SMF characteristics
(magnet materials, dimensions, pole configuration, field
strength); SMF application (frequency, duration, site of
application and support device) and target (target tissue
and distance of magnet from target tissue) was described.
Two points were given if a parameter was described in
enough detail to allow replication of the study protocol
by other investigators. One point was given if the para-
meter was only partially described but enough detail was
given to make reasonable inferences about that para-
meter. For example, if the magnet material was not
described but the manufacturer’s name (e.g. Bioflex) was
provided, and one of the evaluators was familiar enough
with that company’s products to know that the product
was most likely a flexible-type magnet, one point was
given. One point was also given if the target tissue was
not specifically named, but implied. For example, when
dysmenorrhea was treated by placing a magnet over the
lower abdomen, the evaluators assumed the target was
the uterus. The evaluators might also have inferred that
the target was a trigger point on the abdominal wall.
Zero points were assigned if the essential parameter was
not described at all. A perfect QA score is 20.
Three evaluators (APC, a clinician researcher with 14
years clinical experience in the therapeutic use of SMFs;
MM, a biophysicist with 32 years research experience in
SMFs and JS, a magnetic product developer with
15 years experience in magnet design and manufacturing)
met to discuss the extracted data and assign a consensus
QA score for reporting each of the 10 essential SMF
treatment parameters in the 56 studies.
Results
The complete set of extracted data on 10 essential SMF
treatment parameters and the QA scores for the 56 studies
are summarized in supplementary Tables 1 and 2.
Description of Studies
Forty-two studies were conducted in patient populations
(supplementary Table 1) and 14 in healthy volunteers
(supplementary Table 2). The varied clinical conditions
and physiological responses that were evaluated are listed
in Table 2. In the 56 studies, 39 different physiological
or pathological conditions are represented. The most
common clinical diagnosis was osteoarthritis of the knee.
Other conditions were as diverse as peripheral neuro-
pathy, peripheral vascular disease, wound and ulcer
healing, obstructive sleep apnea, tinnitus and a variety
Table 2. Conditions treated with static magnetic field therapy
Physiological Conditions
a Clinical Conditions
b
Muscle strength/physical function
(21, 51, 55, 58, 31)
Chronic pain – headache (40), neck (37), shoulder (38, 39, 47), low back (25, 35, 41, 63), abdominal/genital
(36), pelvic (18, 29), foot (20, 60, 61, 64–66), fibromyalgia (6, 23), myofascial pain (48, 59), carpal tunnel
syndrome (19, 62)
Induced muscle soreness
(17, 46, 49)
Arthritides – knee (34, 35, 52, 53, 67), hip (32)
HR and BP (33) Post surgical – suction lipectomy (42), hallux valgus (54)
Blood flow/temperature
(14, 43–45, 56)
Peripheral vascular disease/leg or foot ulcerations – (13, 28, 30, 57)
Miscellaneous – bronchopulmonary dysplasia (22), sleep apnea (26, 27), urinary incontinence (15), tinnitus (24),
orthodontic safety (16), malignancy (50)
aPhysiological outcomes evaluated in healthy volunteers;
bClinical indications in various patient populations.
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measured were also disparate including: improvement in
muscle strength, muscle soreness post exercise, postural
sway, fine touch, blood flow and heart rate and blood
pressure. The majority of studies were randomized
controlled trials (RCTs) (n=41) that included both
crossover designs and within-subject comparisons.
We identified only two Phase I/II studies that assessed
dose ranging or an evaluation of dosing regimens
(16–50).
Since there were two distinct categories of studies
(healthy volunteers and patient populations), a multi-
variate analysis (MANOVA) was used to compare them
on the 10 treatment parameters evaluated by QA score.
The MANOVA was not significant, P>0.20. Thus, there
was no need to consider reporting quantitative or
qualitative results for the two groups separately.
QA Scores
Percentage of the 56 studies that scored either 2 (fully
described), 1 (partially described) or 0 (not described)
on each essential treatment is delineated in Fig. 1. Two
studies (45–67) out of 56 received a perfect QA score of
20 for detailed reporting of SMF dosing parameters.
Twenty-four studies (43%) scored 15–19 for adequacy of
reporting SMF treatment parameters; 20 studies (36%)
scored 10–14: 9 studies (16%) scored 5–9 and one scored
less than 5. The dosing parameters most consistently well
reported were site, frequency and duration of magnet
application. The parameters most often poorly reported
were characteristics of the magnet (magnet dimensions,
field strength measured at the magnet surface) and
estimated distance of the magnet from the target tissue.
Only 22 (39%) of 56 articles (6, 14, 16, 18, 23, 29, 31–35,
40–42, 44, 45, 52, 53, 56, 59, 64, 67) provided sufficiently
detailed information on SMF treatment parameters to
permit other investigators to attempt study replication.
Discussion
This critical review was undertaken to summarize SMF
research involving the application of magnets in humans;
to critically evaluate quality of reporting10 essential SMF
dosage and treatment parameters and to propose a set of
criteria for reporting SMF treatment parameters in future
clinical trials.
Since research on SMF therapy in humans is in an
emerging state, it is vital that we lay the groundwork for
the rigorous conduct of future clinical trials. A funda-
mental component of trial methodology is the assurance
that optimal SMF dosage and treatment parameters
are established for each clinical condition under study.
If the applied SMF is of insufficient strength to reach its
target or if the frequency or duration of application is
inadequate for the medical condition, trial results might
be invalid or misleading. Such a situation could be
likened to conducting a trial to evaluate the effectiveness
of the antibiotic doxycycline for treating Mycoplasma
pneumonia. If patients in the study are given a single
100mg dose of the antibiotic, the results might show no
significant improvement. It would, however, be erroneous
to infer from these results that doxycycline is ineffective
for treating Mycoplasma pneumonia.
In order to judge the adequacy of SMF exposure for
a particular clinical indication, the magnetic dosage
and treatment regimens need to be reported explicitly.
Clear reporting also allows for accurate replication of
study protocols and comparison of results between
studies. This critical review revealed that the majority
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Figure 1. Quality of reporting 10 static magnetic field (SMF) dosage and treatment parameters was assessed in 56 human studies. Quality Assessment
(QA) score 2=parameter is reported with enough detail for study replication; 1=parameter is reported with insufficient detail to allow study
replication or accurate comparison of results with other studies; 0=parameter is not reported.
136 Static magnetic field therapyof published studies (61%) failed to report enough detail
about 10 essential SMF dosage and/or treatment para-
meters to characterize the SMF that actually reached the
intended target tissue. Of the 10 essential SMF treatment
parameters reported, only site, frequency and duration of
magnet application and magnetic support device were
adequately described. Descriptions of three other essen-
tial treatment parameters specific to SMF dosing, i.e.
identification of the target tissue, measurement of the
SMF at the magnet’s surface and estimation of distance
of target tissue from the magnet, were either not
described or only partially described in a preponderance
of studies (Fig. 1).
In addition, the SMF dosage reported in many of the
studies revealed a limited understanding, on the part of
the investigators, of the physical and biophysical char-
acteristics of magnets that determine the SMF dose
ultimately delivered to the target tissue. Four studies
provided contradictory information about the material
composition of the magnetic devices applied (31, 44,
55, 61). Other studies provided ambiguous descriptions of
the magnetic strength, by not defining whether they were
reporting the manufacturer’s Gauss rating or the surface
field strength. Approximately one-half of the investiga-
tors (13, 15, 17, 21, 22, 24, 26–31, 36, 40, 43, 46–49, 51,
54, 55, 58–62, 68) failed to record measurements of the
field strength at the surface of their magnets. In 16
studies (15–17, 19, 21, 26, 27, 39, 46, 48, 49, 51, 54, 56,
58, 63) there is no mention of which pole configuration
was applied or if the side of the magnet facing the skin
was north, south or alternating polarity.
Despite a lack of established recommendations or
guidelines for SMF dosing regimens, 41 RCTs, were
conducted without prior benefit of Phase I or II trials to
optimize SMF dosage and treatment regimens for the
condition being treated. In fact, this review identified
only two early phase studies that addressed toxicity and/
or dose ranging of SMFs (16, 50).
Limitations to this review
There are a number of limitations in our study. First, we
reviewed only the English language literature. Use of
therapeutic magnets has a long history in China, Japan
and the former Eastern European Bloc countries. Also,
several Asian manufacturers that produce magnetic
bracelets and necklaces have an extensive literature on
clinical usage. Second, although we found a large body of
literature reporting the use of magnets on acupuncture
points, these studies were excluded because we believe
that the practice of acupuncture (a systemic approach)
entails a different therapeutic paradigm than direct
application of the magnet to a localized anatomical site.
Third, evaluators were not blinded to the studies they
scored. Since the available clinical SMF research at this
time is so small, the three evaluators were already
familiar with many of the studies, making it impossible
to blind them as to authorship. Fourth, our search ended
on September 30, 2006, and does not include any
publications after that date.
Conclusion and Directions for Future Research
Complete descriptions of the SMF dose that was
applied to human participants are notably lacking in
the majority of SMF therapy studies published to date.
Without knowing the SMF dose that was delivered to the
target tissue, we cannot draw meaningful inferences
from clinical trial results. As research on SMF therapy
progresses, engineers, physicists and clinicians need to
continue to work together to optimize SMF dosage and
treatment parameters for each clinical condition. Future
publication of SMF studies should include an explicit
assessment of the SMF dosage and treatment parameters
outlined in this review, so as to be able to replicate
previous studies, validly assess outcomes and make
objective, scientific comparisons between studies.
Supplementary Data
Supplementary data are available at eCAM Online.
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